Medicine for treating sinus arrhythmia

Abstract

The invention provides a medicine for treating sinus arrhythmia. The medicine comprises the following components in parts by weight: 9 parts of Sycamore, 6 parts of Cardamom, 6 parts of Astragalus, 3 parts of Fritillaria, 1 part of Elongatus, and loquat 1 part of flower, 0.5 part of hematoxylin and 0.5 part of bamboo. On this basis, 2 parts by weight of mulberry octopus, 2 parts by weight of deer tires or 1 part by weight of mustard greens can be further added. The present invention obtains the above drug formula through rational design of traditional Chinese medicine ingredients, and the drug has outstanding curative effect on sinus arrhythmia, rapid onset of action, and better efficiency and cure rate than the prior art.

Description

technical field [0001] The invention relates to the field of medical and health technologies, in particular to a medicine for treating sinus arrhythmia. Background technique [0002] A heart rhythm that originates in the sinus node is called sinus rhythm. Sinus rhythm is a normal rhythm. Sinus tachycardia, sinus bradycardia, sinus arrhythmia, sinus arrest, and sick sinus syndrome are sinus arrhythmias. A normal adult sinus rhythm with a frequency >100 beats / min is called sinus tachycardia. The frequency of sinus rhythm is time-divided and is called sinus bradycardia. The origin of sinus rhythm has not changed, but the rhythm is irregular, and the P-P interval difference > 0.12s on the same lead is called sinus arrhythmia, which often coexists with sinus bradycardia. The existing drugs for the treatment of sinus arrhythmia have the technical problems of poor curative effect and slow onset, which greatly limit the therapeutic effect of the disease. Contents of the ...

AI Technical Summary

Problems solved by technology

[0003] The present invention aims at the technical defects of the prior art, and provides a sinus arrhythmia treatment drug to solve the technical problems of poor curative effect and slow onset of the sinus arrhythmia treatment drug in the prior art